Osteosarcoma is the most common primary malignant bone tumour. Patients often develop lung
metastasis and have a poor prognosis despite extensive
chemotherapy and surgical resections.
Tissue Factor is associated with poor clinical outcome in a wide range of
cancer types, and promotes angiogenesis and
metastasis. The role of
Tissue Factor in OS tumourigenesis is unknown. Fifty-three
osteosarcoma pre-treatment biopsies and four
osteosarcoma cell lines were evaluated for
Tissue Factor expression, and a possible association with clinical parameters was investigated.
Tissue Factor function was inhibited in an
osteosarcoma cell line (143B) by
shRNA knockdown or specific
antibodies, and pro-tumourigenic gene expression, proliferation,
matrigel invasion and transwell migration was examined. 143B cells were implanted in mice in the presence of
Tissue Factor-
blocking antibodies, and tumour volume, micro-vessel density and
metastases in the lung were evaluated.
Tissue Factor was highly expressed in 73.6 % of
osteosarcoma biopsies, and expression associated significantly with disease-free survival.
Tissue Factor was expressed in all four investigated cell lines.
Tissue Factor was knocked down in 143B cells, which led to reduced expression of
IL-8, CXCL-1, SNAIL and MMP2, but not MMP9.
Tissue Factor knockdown or inhibition with
antibodies reduced
matrigel invasion.
Tissue Factor antibodies limited 143B tumour growth in vivo, and resulted in decreased intra-tumoural micro-vessel density. Furthermore, lung
metastasis from the primary tumour was significantly reduced. Thus,
Tissue Factor expression in
osteosarcoma reduces
metastasis-free survival in patients, and increases pro-tumourigenic behaviour both in vitro and in vivo.